Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator complex subunit 23 (MED23) is a large subunit of the Mediator multiprotein coactivator complex that acts as a critical regulator of transcription by RNA polymerase II in eukaryotes[1][4]. MED23 is part of the Tail module of the Mediator complex, and serves as a direct interface for multiple sequence-specific transcription factors—such as the MAPK-responsive factor Elk-1—thereby integrating extracellular and intracellular signaling information into gene-specific transcriptional responses[1][2][7][8]. The protein has a highly structured, arch-shaped conformation made up of multiple HEAT repeats organized into α-solenoids, facilitating broad protein–protein interactions, including with splicing factors like hnRNP L and epigenetic regulators such as the E3 ubiquitin ligase RNF20/40. Through these interactions, MED23 orchestrates processes ranging from histone modifications (notably, histone H2B mono-ubiquitination) to alternative mRNA splicing, connecting transcriptional activation with chromatin state and RNA metabolism[3][5][8]. Loss or aberrant function of MED23 impacts cell proliferation and differentiation, and aberrant upregulation is associated with tumorigenesis and cancer progression, particularly in lung tissue[3]. There are currently no approved therapeutic agents directly targeting MED23, but it is recognized as a functional and structurally druggable intersection in key gene regulation pathways.
Not applicable; no clinically used drugs are directly targeting MED23, but it is a critical interaction point for transcription factor-mediated gene activation and epigenetic modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator complex subunit 23 (MED23).